» Articles » PMID: 3134297

IL-1 and IFN-gamma Increase Vascular Permeability

Overview
Journal Immunology
Date 1988 Jun 1
PMID 3134297
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

We examined the effect of cytokines on vascular permeability in vivo. Wistar rats received intradermal injections of various cytokine preparations and the permeability index (delta PI) was calculated from the difference between the absorption values of cytokine- and vehicle-treated skin sections after the extraction of accumulated Evans blue vital dye. Injections of a mixture of recombinant interleukin-1 alpha and beta (Il-1 alpha, IL-1 beta) and interferon-gamma (IFN-gamma) caused a maximal increase of permeability after 30 min (delta PI = 2). The administration of single recombinant cytokines revealed that the increase of permeability is mainly due to the action of IL-1 beta (delta PI = 1.4) and IFN-gamma (delta PI = 2.9) (P less than 0.001) at doses of 1-20 microU per injection site. IL-1 alpha slightly increased vascular permeability, whereas recombinant IL-2 and recombinant tumour necrosis factor alpha had no significant effects. Histological observations revealed significantly increased numbers of degranulated mast cells in skin sections pretreated with IL-1 beta (P less than 0.005) or IFN-gamma (P less than 0.001). The cytokine-mediated rise of vascular permeability could be suppressed by pretreatment of the animals with the vasoactive amine antagonizing drugs methysergide, pizotifen and cyproheptadine. Our experiments indicate an important role of IL-1 beta and IFN-gamma as vasoactive substances besides their function as hormone-like messengers between leucocytes.

Citing Articles

Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors.

Hackett J, Ramos N, Barr S, Bross M, Viola N, Gibson H Front Oncol. 2023; 13:1285117.

PMID: 38130991 PMC: 10735274. DOI: 10.3389/fonc.2023.1285117.


More than a key-the pathological roles of SARS-CoV-2 spike protein in COVID-19 related cardiac injury.

Lin Z Sports Med Health Sci. 2023; .

PMID: 37361919 PMC: 10062797. DOI: 10.1016/j.smhs.2023.03.004.


IL-1β Impacts Vascular Integrity and Lymphatic Function in the Embryonic Omentum.

Menendez M, Drozd A, Borawska K, Chmielewska J, Wu M, Griffin C Circ Res. 2022; 130(3):366-383.

PMID: 34986653 PMC: 8813910. DOI: 10.1161/CIRCRESAHA.121.319032.


A hitchhiker's guide through the COVID-19 galaxy.

Felsenstein S, Reiff A Clin Immunol. 2021; 232:108849.

PMID: 34563684 PMC: 8461017. DOI: 10.1016/j.clim.2021.108849.


Molecular Dambusters: What Is Behind Hyperpermeability in Bradykinin-Mediated Angioedema?.

Debreczeni M, Nemeth Z, Kajdacsi E, Farkas H, Cervenak L Clin Rev Allergy Immunol. 2021; 60(3):318-347.

PMID: 33725263 PMC: 7962090. DOI: 10.1007/s12016-021-08851-8.


References
1.
Nawroth P, Bank I, Handley D, Cassimeris J, Chess L, Stern D . Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986; 163(6):1363-75. PMC: 2188127. DOI: 10.1084/jem.163.6.1363. View

2.
Hauser C, Saurat J, Schmitt A, Jaunin F, Dayer J . Interleukin 1 is present in normal human epidermis. J Immunol. 1986; 136(9):3317-23. View

3.
Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen J, Dinarello C, Svenson M . Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science. 1986; 232(4757):1545-7. DOI: 10.1126/science.3086977. View

4.
Rosenstein M, Ettinghausen S, Rosenberg S . Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986; 137(5):1735-42. View

5.
Schwab E, Burkart V, FREYTAG G, Kiesel U, Kolb H . Inhibition of immune-mediated low-dose streptozotocin diabetes by agents which reduce vascular permeability. Immunopharmacology. 1986; 12(1):17-21. DOI: 10.1016/0162-3109(86)90047-0. View